{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"30.7","value":"16.3"},{"groupId":"OG001","lowerLimit":"14.6","upperLimit":"41.9","value":"26.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"Based on Investigator Assessment per IMWG 2016 Criteria, VGPR was defined as serum and urine M-protein detectable by immunofixation (IFE) but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 h. Data are reported for the percentage of participants with a VGPR or better.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with anti-CD38 mAb-naive RRMM received daratumumab at a dose of 1,800 mg by subcutaneous (SC) injection in 28-day treatment cycles.","id":"OG000","title":"RRMM Expansion Part B: Daratumumab"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day treatment cycles.","id":"OG001","title":"RRMM Expansion Part B: GEN3014"}],"paramType":"NUMBER","populationDescription":"Full Analysis set included all enrolled participants who received at least 1 dose of trial drug (GEN3014 or daratumumab SC). Overall number of participants analyzed = participants evaluable for the outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years 3 months","title":"Expansion Part B: Percentage of Participants With Very Good Partial Response (VGPR) or Better","type":"SECONDARY","unitOfMeasure":"percentage of participants"}